OpenAI acquires Orchestra Bio to strengthen biotech AI capabilities

OpenAI acquired Orchestra Bio, a four-year-old AI biotech startup that builds agents to manage drug discovery operations such as finance tracking and clinical trial scheduling. The startup had raised around $20 million as of 2025 from investors including Andreessen Horowitz, Atria, and 8VC. OpenAI said it will integrate Orchestra's team and technology into its AI model Rosalind and the Rosalind Workbench tool to help researchers plan experiments and analyze results. OpenAI counts Moderna and Novo Nordisk among its existing Rosalind customers.